Drug survival of biologic therapies for palmoplantar pustulosis: a nationwide study.

Trine Bertelsen Alexander Egeberg Lone SkovM RasmussenL BryldA FundingK AjgeiyD Thein Aagaard

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

The treatment of PPP poses significant challenges, with limited drug survival observed across all therapies regardless of prior experience with biologics. Ustekinumab demonstrated the longest median drug survival. Notably, patients discontinuing therapy due to inefficacy exhibited higher DLQI scores, highlighting the importance of personalized treatment selection and timely consideration of therapy changes when inefficacy is established.

Keyphrases

end stage renal disease
rheumatoid arthritis
ejection fraction
newly diagnosed
emergency department
drug induced
stem cells
prognostic factors
smoking cessation